MED12 and leiomyoma: Patients with MED12 mutation in leiomyoma have larger tumors (7.99 ± 3.9 cm; p = 0.02), high BMI (33.84 ± 6.9 kg/m2; p = 0.04) and low serum levels of luteinizing hormone (13.8 ± 8.4 mU/L; p = 0.02) compared to women who are not carrying the mutation (Table 4).